# A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

> **NCT02624986** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 25 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Idasanutlin
- **DRUG:** Obinutuzumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02624986
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-23
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624986, "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02624986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*